MCID: BRY005
MIFTS: 40

Beryllium Disease

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Beryllium Disease

MalaCards integrated aliases for Beryllium Disease:

Name: Beryllium Disease 53 72
Subacute Berylliosis 53 72
Acute Berylliosis 53 72
Chronic Pulmonary Berylliosis 53
Reversible Berylliosis 53
Beryllliosis 53

Classifications:



External Ids:

UMLS 72 C0221053 C0340178 C2350873

Summaries for Beryllium Disease

NIH Rare Diseases : 53 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 133DefinitionChronic beryllium disease (CBD) is a granulomatous, interstitial lung disease that occurs in individuals who develop beryllium sensitization (BeS), a cell-mediated immune response to environmental and occupational beryllium exposure. BeS precedes the lung disease that may present with chronic dry cough, fatigue, weight loss, chest pain, and increasing dyspnea.EpidemiologyThe number of workers exposed to beryllium has been estimated at 1 million in the US, although no accurate figure exists for the US or globally. The prevalence of sensitization in those exposed ranges from 1 - 20%. CBD among those with BeS ranges from 15-100%.Clinical descriptionPatients with CBD can range from those who are asymptomatic to those with severe lung dysfunction. Manifestations occur a few months to a many years after exposure to beryllium and include chronic dry cough, dyspnea on exertion, chest pain, fatigue, fever, night sweats and weight loss. Additional extrapulmonary manifestations of dermatitis and skin granulomas have been reported. Progressive pulmonary fibrosis can eventually lead to cor pulmonale and respiratory failure. An increased risk of lung cancer among workers exposed to high levels of beryllium has also been observed.EtiologyCBD is caused by occupational exposure to beryllium and beryllium-containing alloys (usually by inhalation of dust or fumes but also via contact with skin). Over time, in a subset of individuals, a cell-mediated immune response to beryllium may occur, causing the development of sensitized T cells that accumulate within the lungs and eventually form granulomas which can lead to fibrosis. A genetic variant in the HLA-DPB1 gene (6p21.3) with the presence of a glutamic acid at amino acid position 69 has been associated with the development of BeS and CBD.Diagnostic methodsDiagnosis is based on a history of exposure to beryllium, characteristic clinical findings and laboratory testing. BeS can be detected with the beryllium lymphocyte proliferation test (BeLPT) where mononuclear cells from peripheral blood or bronchoalveolar lavage are exposed to beryllium in vitro. Increased proliferation of lymphocytes compared to control cells indicates BeS. Granulomatous and/or mononuclear cell infiltrates in lung tissue, are indicative of CBD. Chest x-ray, CT scan of the lungs, exercise tolerance testing and pulmonary function tests can also aid in the diagnosis.Differential diagnosisThe main differential diagnoses are sarcoidosis (most common) and tuberculosis (see these terms) as well as other occupational lung diseases (i.e. silicosis).Management and treatmentThere is no cure for CBD. Treatment involves cessation of beryllium exposure and use of corticosteroids (prednisone). Early symptomatic disease may be treated with inhaled corticosteroids along with a short acting bronchodilator. Methotrexate and other immunosuppressive therapies can reduce steroid side effects. The efficacy of corticosteroids may be limited and relapses can occur after cessation of therapy or when dose is lowered. Those with advanced disease and major breathing difficulties may require oxygen supplementation. In severe cases, a lung transplant may be suggested. Patients should refrain from smoking. CBD may be prevented by providing exposed workers with respiratory protective devices and protective clothing and by minimizing exposure through use of workplace administration and engineering controls. The BeLPT is used to identify patients early on and to define workplace areas for modification in order to ultimately reduce additional BeS and CBD casesPrognosisPrognosis varies, with some patients remaining clinically stable for many years and some experiencing a gradual worsening of symptoms over time. A debilitating course resulting in respiratory failure is also possible but regular monitoring and treatment can slow down the disease process.Visit the Orphanet disease page for more resources.

MalaCards based summary : Beryllium Disease, also known as subacute berylliosis, is related to berylliosis and chronic beryllium disease. An important gene associated with Beryllium Disease is HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1), and among its related pathways/superpathways are Innate Immune System and Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3. The drugs Infliximab and Analgesics have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells.

Wikipedia : 75 Berylliosis, or chronic beryllium disease (CBD), is a chronic allergic-type lung response and chronic... more...

Related Diseases for Beryllium Disease

Diseases in the Beryllium Disease family:

Chronic Beryllium Disease

Diseases related to Beryllium Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 berylliosis 32.1 HLA-DRB1 HLA-DPB1 HLA-DPA1
2 chronic beryllium disease 31.9 TNF HLA-DRB1 HLA-DQB1 HLA-DPB1 HLA-DPA1
3 sarcoidosis 1 30.0 TNF HLA-DRB1
4 autoimmune disease 29.1 TNF HLA-DRB1 HLA-DQB1
5 lung disease 10.7
6 allergic hypersensitivity disease 10.3
7 neonatal lupus erythematosus 10.3 HLA-DQA1 HLA-DPB1
8 pulmonary sarcoidosis 10.2
9 achalasia, familial esophageal 10.2 HLA-DQB1 HLA-DQA1
10 idiopathic interstitial pneumonia 10.2
11 pulmonary fibrosis 10.2
12 congenital toxoplasmosis 10.1 HLA-DQB1 HLA-DQA1
13 pulmonary hypertension 10.1
14 bronchiectasis 10.1
15 limbic encephalitis with lgi1 antibodies 10.1 HLA-DRB1 HLA-DQB1
16 cervical dystonia 10.1 HLA-DQB1 HLA-DQA1
17 narcolepsy 2 10.1 HLA-DRB1 HLA-DQB1
18 autoimmune polyglandular syndrome type 3 10.1 HLA-DRB1 HLA-DQB1
19 hypersomnia 10.1 HLA-DRB1 HLA-DQB1
20 type ii mixed cryoglobulinemia 10.1 HLA-DRB1 HLA-DQB1
21 lichen planopilaris 10.1 HLA-DRB1 HLA-DQB1
22 metal allergy 10.1 HLA-DRB1 HLA-DQB1
23 recurrent respiratory papillomatosis 10.1 HLA-DRB1 HLA-DQB1
24 neuromyelitis optica 10.1 HLA-DRB1 HLA-DPB1
25 narcolepsy 1 10.1 HLA-DRB1 HLA-DQB1
26 lung cancer 10.1
27 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
28 pneumoconiosis 10.1
29 anthracosis 10.1
30 pneumothorax 10.1
31 interstitial lung disease 10.1
32 dermatitis herpetiformis 10.1 HLA-DQB1 HLA-DQA1
33 hirata disease 10.1 HLA-DRB1 HLA-DQA1
34 lichen sclerosus 10.1 HLA-DRB1 HLA-DQB1
35 eosinophilia-myalgia syndrome 10.1 HLA-DRB1 HLA-DQA1
36 pityriasis rosea 10.1 HLA-DRB1 HLA-DQB1
37 whipple disease 10.1 HLA-DRB1 HLA-DQB1
38 pediatric multiple sclerosis 10.1 HLA-DRB1 HLA-DQB1
39 osteonecrosis of the jaw 10.1 HLA-DRB1 HLA-DQB1
40 myelitis 10.1 TNF HLA-DPB1
41 histoplasmosis 10.0 HLA-DRB1 HLA-DQA1
42 peanut allergy 10.0 HLA-DRB1 HLA-DQB1
43 pure red-cell aplasia 10.0 HLA-DRB1 HLA-DQB1
44 ocular cicatricial pemphigoid 10.0 HLA-DRB1 HLA-DQB1
45 paraneoplastic pemphigus 10.0 HLA-DRB1 HLA-DQB1
46 proteasome-associated autoinflammatory syndrome 1 9.9
47 exanthem 9.9
48 inflammatory bowel disease 9.9
49 tetanus 9.9
50 adult respiratory distress syndrome 9.9

Graphical network of the top 20 diseases related to Beryllium Disease:



Diseases related to Beryllium Disease

Symptoms & Phenotypes for Beryllium Disease

Drugs & Therapeutics for Beryllium Disease

Drugs for Beryllium Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 1, Phase 2 170277-31-3
2 Analgesics Phase 1, Phase 2
3 Mesalamine Phase 1, Phase 2 89-57-6
4 Analgesics, Non-Narcotic Phase 1, Phase 2
5 Peripheral Nervous System Agents Phase 1, Phase 2
6 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
7 Anti-Inflammatory Agents Phase 1, Phase 2
8 Antirheumatic Agents Phase 1, Phase 2
9 Gastrointestinal Agents Phase 1, Phase 2
10 Dermatologic Agents Phase 1, Phase 2
11
Heparin Approved, Investigational 9005-49-6 46507594 772
12
Acetylcysteine Approved, Investigational 616-91-1 12035
13 Pharmaceutical Solutions
14 calcium heparin
15 N-monoacetylcystine
16 Respiratory System Agents
17 Antioxidants
18 Free Radical Scavengers
19 Antidotes
20 Anti-Infective Agents
21 Protective Agents
22 cysteine
23 Expectorants
24 Antiviral Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Targeting Oxidative Stress in Chronic Beryllium Disease Completed NCT01088243 Phase 1, Phase 2 Mesalamine;Placebo
2 Clinical Efficacy of Remicade in Chronic Beryllium Disease: A Randomized, Double-Blind, Placebo-Controlled, Investigator Initiated Trial Terminated NCT00111917 Phase 1, Phase 2 Infliximab
3 The Role of JAK2 in Alveolar Macrophages in Chronic Beryllium Disease Unknown status NCT02596347
4 Shared Genetic Susceptibility in CBD and Sarcoidosis Completed NCT00560989
5 The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis Completed NCT01587001 Placebo
6 Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Recruiting NCT02604693

Search NIH Clinical Center for Beryllium Disease

Genetic Tests for Beryllium Disease

Anatomical Context for Beryllium Disease

MalaCards organs/tissues related to Beryllium Disease:

41
Lung, Testes, T Cells, Skin, Monocytes

Publications for Beryllium Disease

Articles related to Beryllium Disease:

(show top 50) (show all 442)
# Title Authors PMID Year
1
Polymorphism of FCGR3A gene in chronic beryllium disease. 38
30245507 2019
2
New insight in beryllium toxicity excluding exposure to beryllium-containing dust: accumulation patterns, target organs, and elimination. 38
30891623 2019
3
Occupational exposure to beryllium in French industries. 38
30570429 2019
4
Interstitial Lung Diseases in Developing Countries. 38
30741505 2019
5
DNA Methylation Changes in Lung Immune Cells Are Associated with Granulomatous Lung Disease. 38
30141971 2019
6
TLR9 and IL-1R1 Promote Mobilization of Pulmonary Dendritic Cells during Beryllium Sensitization. 38
30185516 2018
7
Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT). 38
29574954 2018
8
[Differential Diagnosis of Mediastinal and Hilar Lymphadenopathy with Focus on Occupational Diseases]. 38
29046010 2018
9
Effect of inhaled corticosteroids on lung function in chronic beryllium disease. 38
29453139 2018
10
Immunologic Effects of Beryllium Exposure. 38
29676647 2018
11
A Pilot Study Assessing the Ability of 5-Aminosalicylic Acid to Modulate the Immune Response in Chronic Beryllium Disease. 38
29676640 2018
12
5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects. 38
29080069 2018
13
Interstitial pneumonia in a glassblower: think to chronic beryllium disease! 38
31011396 2018
14
Clinical Course of Sarcoidosis in World Trade Center-Exposed Firefighters. 38
29066387 2018
15
High-Affinity Interactions of Beryllium(2+) with Phosphatidylserine Result in a Cross-Linking Effect Reducing Surface Recognition of the Lipid. 38
28872302 2017
16
Clinical tool for disease phenotyping in granulomatous lung disease. 38
29145499 2017
17
Occupational Exposure to Beryllium. Final rule. 38
28071878 2017
18
A mortality study of beryllium workers. 38
27766788 2016
19
Chronic Beryllium Disease: The Search for a Dose-Response. 38
27820771 2016
20
Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease. 38
27414009 2016
21
Beryllium disease and sarcoidosis: still besties after all these years? 38
27246078 2016
22
Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis. 38
27103383 2016
23
CpG promoter methylation status is not a prognostic indicator of gene expression in beryllium challenge. 38
26673671 2016
24
Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice. 38
26129650 2016
25
Elemental analysis of occupational granulomatous lung disease by electron probe microanalyzer with wavelength dispersive spectrometer: Two case reports. 38
27330955 2016
26
Identification of metal sensitization in sarcoid-like metal-exposed patients by the MELISA® lymphocyte proliferation test - a pilot study. 38
27076838 2016
27
[A experiment research of beryllium oxide induced oxidative lung injury and the protective effects of LBP in rats]. 38
26653647 2015
28
Gene-environment interaction from international cohorts: impact on development and evolution of occupational and environmental lung and airway disease. 38
26024343 2015
29
Accelerator mass spectrometry detection of beryllium ions in the antigen processing and presentation pathway. 38
24932923 2015
30
Beryllium and other metal-induced lung disease. 38
25602804 2015
31
Genetic susceptibility to beryllium: a case-referent study of men and women of working age with sarcoidosis or other chronic lung disease. 38
25305207 2015
32
Beryllium increases the CD14(dim)CD16+ subset in the lung of chronic beryllium disease. 38
25689051 2015
33
The beryllium bronchoalveolar lavage lymphocyte proliferation test: indicator of beryllium sensitization, inflammation or both? 38
25942054 2015
34
p38 Mitogen-Activated Protein Kinase in beryllium-induced dendritic cell activation. 38
25454621 2014
35
An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. 38
25398119 2014
36
Illness absences among beryllium sensitized workers. 38
25211750 2014
37
Quantification and micron-scale imaging of spatial distribution of trace beryllium in shrapnel fragments and metallurgic samples with correlative fluorescence detection method and secondary ion mass spectrometry (SIMS). 38
25146877 2014
38
Beryllium BioBank: 2. Lymphocyte proliferation testing. 38
25099413 2014
39
Beryllium Biobank 3: considerations for improving chronic beryllium disease screening. 38
25099414 2014
40
Exposure factors associated with chronic beryllium disease development in Beryllium BioBank participants. 38
25099412 2014
41
Unsuspected exposure to beryllium: potential implications for sarcoidosis diagnoses. 38
25078645 2014
42
Structural basis of chronic beryllium disease: linking allergic hypersensitivity and autoimmunity. 38
24995984 2014
43
Sarcoidosis and chronic beryllium disease: similarities and differences. 38
25007084 2014
44
Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease. 38
24912188 2014
45
Identification of multiple public TCR repertoires in chronic beryllium disease. 38
24719461 2014
46
Chronic Beryllium Disease: revealing the role of beryllium ion and small peptides binding to HLA-DP2. 38
25369028 2014
47
T cell recognition of beryllium. 38
23978481 2013
48
Beryllium disease among construction trade workers at Department of Energy nuclear sites. 38
23794247 2013
49
Impaired function of CTLA-4 in the lungs of patients with chronic beryllium disease contributes to persistent inflammation. 38
23851684 2013
50
Developing effective health and safety training materials for workers in beryllium-using industries. 38
23787563 2013

Variations for Beryllium Disease

Expression for Beryllium Disease

Search GEO for disease gene expression data for Beryllium Disease.

Pathways for Beryllium Disease

Pathways related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
2
Show member pathways
13.51 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
3
Show member pathways
13.2 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
4
Show member pathways
13.18 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
5
Show member pathways
13 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
6
Show member pathways
12.78 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
7
Show member pathways
12.77 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
8
Show member pathways
12.71 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
9
Show member pathways
12.51 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
10
Show member pathways
12.47 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
11
Show member pathways
12.42 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
12
Show member pathways
12.31 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
13
Show member pathways
12.29 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
14 12.19 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
15
Show member pathways
12.17 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
16 12.1 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
17 12.06 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
18
Show member pathways
12.01 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
19
Show member pathways
11.9 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
20 11.89 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
21
Show member pathways
11.89 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
22 11.89 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
23 11.84 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
24 11.73 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
25 11.7 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
26 11.5 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
27 11.42 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
28 11.1 TNF HLA-DRB1
29 11.07 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

GO Terms for Beryllium Disease

Cellular components related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.88 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
2 Golgi membrane GO:0000139 9.88 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
3 Golgi apparatus GO:0005794 9.86 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
4 lysosomal membrane GO:0005765 9.85 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
5 endoplasmic reticulum membrane GO:0005789 9.84 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
6 endosome GO:0005768 9.83 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
7 endosome membrane GO:0010008 9.83 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
8 cell surface GO:0009986 9.81 TNF HLA-DRB1 HLA-DPB1 HLA-DPA1
9 lysosome GO:0005764 9.8 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
10 trans-Golgi network membrane GO:0032588 9.8 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
11 endocytic vesicle membrane GO:0030666 9.77 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
12 ER to Golgi transport vesicle membrane GO:0012507 9.72 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
13 transport vesicle membrane GO:0030658 9.65 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
14 clathrin-coated endocytic vesicle membrane GO:0030669 9.55 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
15 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
16 MHC class II protein complex GO:0042613 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
17 integral component of membrane GO:0016021 10.04 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
18 plasma membrane GO:0005886 10.02 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

Biological processes related to Beryllium Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 TNF HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
2 immune system process GO:0002376 9.78 HLA-DRB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
3 T cell receptor signaling pathway GO:0050852 9.72 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
4 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.65 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
5 positive regulation of interferon-gamma production GO:0032729 9.58 TNF HLA-DPB1 HLA-DPA1
6 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
7 positive regulation of T cell proliferation GO:0042102 9.51 HLA-DPB1 HLA-DPA1
8 positive regulation of T cell activation GO:0050870 9.49 HLA-DPB1 HLA-DPA1
9 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.46 HLA-DRB1 HLA-DQB1
10 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.43 HLA-DRB1 HLA-DQB1
11 antigen processing and presentation GO:0019882 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1
12 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

Molecular functions related to Beryllium Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.26 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPA1
2 peptide antigen binding GO:0042605 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-DPB1 HLA-DPA1

Sources for Beryllium Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....